Aurinia Pharmaceuticals has filed a patent for using voclosporin to treat or prevent coronavirus infection in immunosuppressed individuals. The method involves administering a therapeutically effective amount of voclosporin to the subject. GlobalData’s report on Aurinia Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Aurinia Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aurinia Pharmaceuticals, cyclosporin derivatives was a key innovation area identified from patents. Aurinia Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Method of using voclosporin to treat or prevent coronavirus infection